Evidence that many people may stop using the weight-loss therapies not long after starting is influencing a debate over their cost to patients, employers, and government health plans.
Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular medications two years later, according to an analysis of U.S. pharmacy claims provided to Reuters that also showed a steady decline in use over time.
